Should High-Risk Smoldering Myeloma Be Treated? Exploring CAR-T & Combination Therapy Options

Event Description
Should high-risk smoldering multiple myeloma (HR-SMM) be treated, and if so, how? In this webinar, Dr. Omar Nadeem will discuss the latest research on early treatment strategies, including CAR-T and combination therapy. Learn who may benefit from early treatment, the potential risks and benefits, and what these advances mean for the future of myeloma care. Whether you're a patient, caregiver, or advocate, this webinar will provide valuable insights to help you make informed decisions. Register now to join the discussion!
Schedule & Agenda

Cynthia introduces the agenda of the event and featured speaker Dr. Omar Nadeem

Cynthia introduces the agenda of the event and featured speaker Dr. Omar Nadeem

Dr. Nadeem discusses the latest research on early treatment strategies, including CAR-T and combination therapy

Dr. Nadeem discusses the latest research on early treatment strategies, including CAR-T and combination therapy
Type your questions in the chat and we will answer them!
Type your questions in the chat and we will answer them!
Speakers & Moderators

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.

Dr. Nadeem completed his internal medicine residency training at Dartmouth-Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He is board certified in internal medicine, hematology and medical oncology. He joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 2018. He is an Instructor in Medicine at Harvard Medical School and serves as the Clinical Director of Myeloma Cellular Therapies Program and Director of Myeloma and Plasma Cell Pathways at the Dana-Farber Cancer Institute. His clinical and research interests include studying the role of immunotherapy and cellular therapies in multiple myeloma, with particular focus on CAR T-cell therapy. He serves as a principal investigator of several clinical trials in smoldering multiple myeloma, newly diagnosed disease and relapsed and refractory multiple myeloma. He also attends in the Center of Prevention of Progression (CPOP) clinic at DFCI, which is focused on management of patients with precursor plasma cell disorders.
Join the Conversation
This event is part of the Watch and Wait group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org

Get the Latest Blood Cancer Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.